Molnupiravir, a novel antiviral drug developed by Merck and Ridgeback Biotherapeutics, has recently been approved by the FDA for emergency use authorization in treating mild-to-moderate COVID-19 in adults who are at high risk of progression to severe disease. The medication is unique in its mechanism of action, as it targets the RNA polymerase enzyme responsible for viral replication rather than the virus itself. It has shown promising results in clinical trials, reducing hospitalization rates and accelerating viral clearance within patients.
Developed under partnership with Sahar Pharma, Molnupiravir offers a new approach to combating COVID-19 and has brought renewed hope to the ongoing battle against the pandemic. Its continued development could lead to further breakthrough treatments for infectious diseases caused by RNA viruses.
Inquire About this product
